List view / Grid view
11 July 2016 | By Victoria White, Digital Content Producer
The SMC has accepted five new medicines for routine use in NHS Scotland including lung cancer treatments nivolumab and crizotinib...
29 March 2016 | By Victoria White
The FDA have issued a CRL to include new data in the clinical trials section of the US label of Brintellix for treating aspects of cognitive dysfunction in MDD...
14 March 2016 | By Victoria White
The Phase III programme will consist of two pivotal trials. Two doses of Lu AF35700 will be tested in patients with treatment resistant schizophrenia...
4 February 2016 | By Victoria White
The FDA Advisory Committee reviewed data from studies designed to assess the effect of Brintellix on cognitive dysfunction in adult patients with MDD...
24 June 2015 | By Victoria White
Otsuka and Lundbeck have announced newly released subgroup analysis of data from the QUALIFY study of Abilify Maintena (aripiprazole once-monthly)...
5 March 2015 | By H. Lundbeck A/S
Lundbeck today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for a Type-II Variation related to the update of the European summary of the product characteristics (SmPC) for Brintellix...
11 December 2014 | By H. Lundbeck A/S
... presented at the American College of Neuropsychopharmacology annual meeting.
16 September 2014 | By Lundbeck
...and will be introduced in several other European and International Markets during 2014 and 2015.
19 June 2014 | By H. Lundbeck A/S
Lundbeck will present results about sexual functioning from a head-to-head study of Brintellix® (vortioxetine) vs. escitalopram in patients with well treated Major Depressive Disorder...
29 May 2014 | By H. Lundbeck A/S
Data highlights safety and efficacy profile of Brintellix, including difficult to treat patients and special patient populations...
20 May 2014 | By Lundbeck
H. Lundbeck A/S is involved in new research on Parkinson’s disease, which may be the first step towards a new and significantly improved treatment of the debilitating and devastating disease...
6 May 2014 | By H. Lundbeck A/S
H. Lundbeck A/S has once again received support and recognition for its research on Parkinson’s disease through a grant from The Michael J. Fox Foundation for Parkinson’s Research...
6 May 2014 | By H. Lundbeck A/S
H. Lundbeck A/S announced that clinical and pre-clinical data highlighting the company’s ongoing commitment to advancing the science and treatment of depression will be presented at the American Psychiatric Association 167th Annual Meeting...
7 April 2014 | By Lundbeck
H. Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical Europe Ltd. (Otsuka) announced results from the final analysis of a mirror-image study showing statistically significant reductions (p
1 April 2014 | By Lundbeck
H. Lundbeck A/S, together with a number of other companies, is now entering into a collaboration with the Lieber Institute, which has the world’s largest collection of human brains from patients with psychiatric disorders...
